Management of renal failure in multiple myeloma

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Renal failure is a common complication observed in patients with multiple myeloma (MM) and other plasma cell cancers that is generally associated with an adverse clinical outcome[1]. The optimal management of MM patients with renal disease presents a challenge. As numerous drugs are cleared via the kidneys, renal impairment imposes limitation on anti-myeloma therapeutics through decreased drug clearance and enhanced toxicity[1]. Thus optimal renal function assessment is essential, often involving measurements of glomerular filtration rate (GFR), serum creatinine (sCr) levels, and creatinine clearance (CrCl) rates. However, the exact definition and incidence of “renal failure” varies among investigators and depends on the measurement parameter being used. The Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney Foundation defines kidney disease as either kidney damage or a decreased GFR of <60 ml/min/1.73 m2 for ≥3 months[2]. Using the KDOQI criteria, we observed that 54% of patients seen at Roswell Park Cancer Institute presented with stage ≥3 (<60 ml/min/1.73 m2) kidney disease at the time of diagnosis[3]. When sCr is used to assess kidney function, a value of ≥2 mg/dl specifies impairment and is present in approximately 20% of MM patients[4–7]. Although measurement of sCr is simple and relatively the least cumbersome approach, it varies with age, sex and muscle mass, and is not an absolute reflection of renal function[8]. Patients with MM tend to be elderly with normal or low muscle mass and thus sCr may be lower for a given GFR or CrCl rate. As such, the extent of renal insufficiency is often underestimated in these patients when sCr alone is utilized to assess kidney function[8–13].

Original languageEnglish (US)
Title of host publicationMyeloma: Pathology, Diagnosis, and Treatment
PublisherCambridge University Press
Pages255-275
Number of pages21
Volume9781107010574
ISBN (Print)9780511862465, 9781107010574
DOIs
StatePublished - Jan 1 2011

Fingerprint

Multiple Myeloma
Renal Insufficiency
Kidney
Creatinine
Kidney Diseases
Glomerular Filtration Rate
Serum
Muscles
Plasma Cells
Pharmaceutical Preparations
Neoplasms
Research Personnel
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Paulus, A., Advani, P., Aslam, N., & Chanan Khan, A. A. (2011). Management of renal failure in multiple myeloma. In Myeloma: Pathology, Diagnosis, and Treatment (Vol. 9781107010574, pp. 255-275). Cambridge University Press. https://doi.org/10.1017/CBO9780511862465.019

Management of renal failure in multiple myeloma. / Paulus, Aneel; Advani, Pooja; Aslam, Nabeel; Chanan Khan, Asher A.

Myeloma: Pathology, Diagnosis, and Treatment. Vol. 9781107010574 Cambridge University Press, 2011. p. 255-275.

Research output: Chapter in Book/Report/Conference proceedingChapter

Paulus, A, Advani, P, Aslam, N & Chanan Khan, AA 2011, Management of renal failure in multiple myeloma. in Myeloma: Pathology, Diagnosis, and Treatment. vol. 9781107010574, Cambridge University Press, pp. 255-275. https://doi.org/10.1017/CBO9780511862465.019
Paulus A, Advani P, Aslam N, Chanan Khan AA. Management of renal failure in multiple myeloma. In Myeloma: Pathology, Diagnosis, and Treatment. Vol. 9781107010574. Cambridge University Press. 2011. p. 255-275 https://doi.org/10.1017/CBO9780511862465.019
Paulus, Aneel ; Advani, Pooja ; Aslam, Nabeel ; Chanan Khan, Asher A. / Management of renal failure in multiple myeloma. Myeloma: Pathology, Diagnosis, and Treatment. Vol. 9781107010574 Cambridge University Press, 2011. pp. 255-275
@inbook{bf7ae2f0110642bc85ce2d4f5819c6c3,
title = "Management of renal failure in multiple myeloma",
abstract = "Introduction Renal failure is a common complication observed in patients with multiple myeloma (MM) and other plasma cell cancers that is generally associated with an adverse clinical outcome[1]. The optimal management of MM patients with renal disease presents a challenge. As numerous drugs are cleared via the kidneys, renal impairment imposes limitation on anti-myeloma therapeutics through decreased drug clearance and enhanced toxicity[1]. Thus optimal renal function assessment is essential, often involving measurements of glomerular filtration rate (GFR), serum creatinine (sCr) levels, and creatinine clearance (CrCl) rates. However, the exact definition and incidence of “renal failure” varies among investigators and depends on the measurement parameter being used. The Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney Foundation defines kidney disease as either kidney damage or a decreased GFR of <60 ml/min/1.73 m2 for ≥3 months[2]. Using the KDOQI criteria, we observed that 54{\%} of patients seen at Roswell Park Cancer Institute presented with stage ≥3 (<60 ml/min/1.73 m2) kidney disease at the time of diagnosis[3]. When sCr is used to assess kidney function, a value of ≥2 mg/dl specifies impairment and is present in approximately 20{\%} of MM patients[4–7]. Although measurement of sCr is simple and relatively the least cumbersome approach, it varies with age, sex and muscle mass, and is not an absolute reflection of renal function[8]. Patients with MM tend to be elderly with normal or low muscle mass and thus sCr may be lower for a given GFR or CrCl rate. As such, the extent of renal insufficiency is often underestimated in these patients when sCr alone is utilized to assess kidney function[8–13].",
author = "Aneel Paulus and Pooja Advani and Nabeel Aslam and {Chanan Khan}, {Asher A}",
year = "2011",
month = "1",
day = "1",
doi = "10.1017/CBO9780511862465.019",
language = "English (US)",
isbn = "9780511862465",
volume = "9781107010574",
pages = "255--275",
booktitle = "Myeloma: Pathology, Diagnosis, and Treatment",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Management of renal failure in multiple myeloma

AU - Paulus, Aneel

AU - Advani, Pooja

AU - Aslam, Nabeel

AU - Chanan Khan, Asher A

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Introduction Renal failure is a common complication observed in patients with multiple myeloma (MM) and other plasma cell cancers that is generally associated with an adverse clinical outcome[1]. The optimal management of MM patients with renal disease presents a challenge. As numerous drugs are cleared via the kidneys, renal impairment imposes limitation on anti-myeloma therapeutics through decreased drug clearance and enhanced toxicity[1]. Thus optimal renal function assessment is essential, often involving measurements of glomerular filtration rate (GFR), serum creatinine (sCr) levels, and creatinine clearance (CrCl) rates. However, the exact definition and incidence of “renal failure” varies among investigators and depends on the measurement parameter being used. The Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney Foundation defines kidney disease as either kidney damage or a decreased GFR of <60 ml/min/1.73 m2 for ≥3 months[2]. Using the KDOQI criteria, we observed that 54% of patients seen at Roswell Park Cancer Institute presented with stage ≥3 (<60 ml/min/1.73 m2) kidney disease at the time of diagnosis[3]. When sCr is used to assess kidney function, a value of ≥2 mg/dl specifies impairment and is present in approximately 20% of MM patients[4–7]. Although measurement of sCr is simple and relatively the least cumbersome approach, it varies with age, sex and muscle mass, and is not an absolute reflection of renal function[8]. Patients with MM tend to be elderly with normal or low muscle mass and thus sCr may be lower for a given GFR or CrCl rate. As such, the extent of renal insufficiency is often underestimated in these patients when sCr alone is utilized to assess kidney function[8–13].

AB - Introduction Renal failure is a common complication observed in patients with multiple myeloma (MM) and other plasma cell cancers that is generally associated with an adverse clinical outcome[1]. The optimal management of MM patients with renal disease presents a challenge. As numerous drugs are cleared via the kidneys, renal impairment imposes limitation on anti-myeloma therapeutics through decreased drug clearance and enhanced toxicity[1]. Thus optimal renal function assessment is essential, often involving measurements of glomerular filtration rate (GFR), serum creatinine (sCr) levels, and creatinine clearance (CrCl) rates. However, the exact definition and incidence of “renal failure” varies among investigators and depends on the measurement parameter being used. The Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney Foundation defines kidney disease as either kidney damage or a decreased GFR of <60 ml/min/1.73 m2 for ≥3 months[2]. Using the KDOQI criteria, we observed that 54% of patients seen at Roswell Park Cancer Institute presented with stage ≥3 (<60 ml/min/1.73 m2) kidney disease at the time of diagnosis[3]. When sCr is used to assess kidney function, a value of ≥2 mg/dl specifies impairment and is present in approximately 20% of MM patients[4–7]. Although measurement of sCr is simple and relatively the least cumbersome approach, it varies with age, sex and muscle mass, and is not an absolute reflection of renal function[8]. Patients with MM tend to be elderly with normal or low muscle mass and thus sCr may be lower for a given GFR or CrCl rate. As such, the extent of renal insufficiency is often underestimated in these patients when sCr alone is utilized to assess kidney function[8–13].

UR - http://www.scopus.com/inward/record.url?scp=84927113186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927113186&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511862465.019

DO - 10.1017/CBO9780511862465.019

M3 - Chapter

SN - 9780511862465

SN - 9781107010574

VL - 9781107010574

SP - 255

EP - 275

BT - Myeloma: Pathology, Diagnosis, and Treatment

PB - Cambridge University Press

ER -